SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16047)9/9/2002 1:19:17 AM
From: aknahow  Read Replies (1) | Respond to of 17367
 
O.K. Giroirs statement is correct, as it referred to the P II U.S. trial. But the Nova program, at least for me, created the impression that the results being talked about were from the P III U.S./U.K. phase III trial.

Thought the U.S. P II was even better than a 25% reduction in mortality. What else am I missing?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News